Literature DB >> 2767243

The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity.

B Zhang1, S M Lewis.   

Abstract

Employing radionuclide scanning, the volume of the spleen, its red cell pool and plasma pool have been measured in vivo, and the relative proportions of cellularity and vascularity of the spleen have been calculated in 51 patients with myeloproliferative and lymphoproliferative disorders. In primary proliferative polycythaemia (polycythaemia vera), the increase of spleen size was attributed mainly to the increase of splenic vascularity; in myelofibrosis and in hairy cell leukaemia, the increase of spleen size was associated with increase in both splenic vascularity and cellularity, whilst in CGL and CLL the increase was attributed more to cellularity than to vascularity.

Entities:  

Mesh:

Year:  1989        PMID: 2767243     DOI: 10.1111/j.1600-0609.1989.tb01253.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  The spleen in osteomyelofibrosis. A morphological and immunohistochemical study of 30 cases.

Authors:  S Falk; D Mix; H J Stutte
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

Review 3.  Multimodality imaging of osseous involvement In haematological malignancies.

Authors:  Abhishek R Keraliya; Katherine M Krajewski; Jyothi P Jagannathan; Atul B Shinagare; Marta Braschi-Amirfarzan; Sree H Tirumani; Nikhil H Ramaiya
Journal:  Br J Radiol       Date:  2016-01-19       Impact factor: 3.039

4.  JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.

Authors:  Chi Hua Sarah Lin; Kenneth Kaushansky; Huichun Zhan
Journal:  Blood Cells Mol Dis       Date:  2016-11-04       Impact factor: 3.039

5.  C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.

Authors:  Xiaoli Wang; Sool Yeon Cho; Cing Siang Hu; Daniel Chen; John Roboz; Ronald Hoffman
Journal:  Exp Hematol       Date:  2014-11-08       Impact factor: 3.084

6.  How I treat splenomegaly in myelofibrosis.

Authors:  F Cervantes
Journal:  Blood Cancer J       Date:  2011-10-07       Impact factor: 11.037

7.  The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.

Authors:  Stefanie Slot; Niels W C J van de Donk; René H J Otten; Bouke J H Boden; Josée Zijlstra; Pieter G H M Raijmakers; Sonja Zweegman
Journal:  Cancer Imaging       Date:  2021-04-20       Impact factor: 3.909

8.  Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

Authors:  S E M Herman; C U Niemann; M Farooqui; J Jones; R Z Mustafa; A Lipsky; N Saba; S Martyr; S Soto; J Valdez; J A Gyamfi; I Maric; K R Calvo; L B Pedersen; C H Geisler; D Liu; G E Marti; G Aue; A Wiestner
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528

9.  A case of massive splenomegaly due to chronic myeloproliferative neoplasm.

Authors:  Zachary G Jacobs; Bongani Kaimila; Peter M Wasswa; Thuy Bui
Journal:  Malawi Med J       Date:  2018-03       Impact factor: 0.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.